Here's Wouldn't Touch Moderna: Why I Won't Bet on Its Next Growth Engine
Moderna surged on pandemic-era demand. But what comes next? This piece examines why some investors are wary, what a t...
Discover key insights every first time investor should know. Equip yourself with the knowledge for a successful and rewarding investing experience.
28,352 articlesModerna surged on pandemic-era demand. But what comes next? This piece examines why some investors are wary, what a t...
A practical, investor-focused look at delcath (dcth) 2025 earnings prospects. We break down the catalysts, risks, and...
QuantumScape has fallen hard in early 2026. This guide walks you through what would move the stock higher, what could...
As AI demand grows, one data-center play stands out for potential upside. This piece breaks down the catalysts, risks...
Oil tensions linked to Iran have put pressure on stocks, lifting energy prices and weighing on the S&P 500 and Nasdaq...
AbbVie’s stock has climbed since 2024, yet a stubborn balance sheet and looming biosimilar erosion create a cautious ...
Ford investors are watching for signs of real momentum beyond headlines. This article breaks down the latest little g...
As 2026 unfolds, investors eye three key covered call ETFs for steady monthly income. This analysis compares ISPY, JE...
As AI surges, regulators move faster than hype. Markets put odds of model access curbs at about 27.5% for 2026, reviv...
Investors are watching a pivotal Starship test as markets gauge the odds of a SpaceX IPO. A successful launch could s...
A single government contract accounted for 20.9% of SpaceX’s 2025 revenue, a figure that underscores the fragility of...
Nebius Group has rocketed more than 240% this year. Before you jump in, learn how to weigh momentum against fundament...